BriaCell Therapeutics (BCTX) vs NextCure (NXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NextCure (NXTC) has outperformed BriaCell Therapeutics (BCTX) over the past year, losing 1.0% versus a loss of 68.3%. Over five years, NXTC leads with a -93.5% price change compared with -95.1% for BCTX. BriaCell Therapeutics is the larger company by market cap ($34.1 million vs $31.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCTX | NXTC |
|---|---|---|
| Share price | $3.92 | $6.78 |
| Market cap | $34.10M | $31.03M |
| 1-day change | -2.00% | +3.35% |
| YTD return | -43.74% | -52.22% |
| 1-year return | -68.33% | -1.02% |
| 5-year return | -95.12% | -93.53% |
| EPS (TTM) | $-0.92 | $-8.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.68 | $15.74 |
| 52-week low | $2.60 | $1.55 |
| Distance from 52-week high | -73.30% | -56.93% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +194.99% |
| Average volume | 280.62K | 2.11M |
| Shares outstanding | 8.70M | 4.58M |
| Employees | — | 40 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NXTC has outperformed BCTX by 67.3 percentage points over the past year.
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Healthcare · Biotechnology
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Healthcare · Biotechnology · 40 employees
BCTX vs NXTC FAQ
Which is bigger, BriaCell Therapeutics or NextCure?
BriaCell Therapeutics (BCTX) is larger, with a market capitalization of $34.10M compared with $31.03M for NextCure (NXTC).
Which stock has performed better over the past year, BCTX or NXTC?
NXTC returned -1.02% over the past 12 months, compared with -68.33% for BCTX (price return, excluding dividends). Past performance does not predict future results.
Are BriaCell Therapeutics and NextCure in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.